Printer Friendly

Assessment of Economic Burden of Concurrent Measles and Rubella Outbreaks, Romania, 2011-2012.

Outbreaks of measles and rubella constitute serious public health events and entail a vigorous response from public health agencies. A typical response could include a range of complex activities, including isolation of case-patients, case-contact tracing, assessment of disease or vaccination history of each case-patient, identification of potentially susceptible persons, and, if required, vaccination or quarantine (1). Economic impact studies of measles and rubella outbreaks in high-income countries illustrate a high cost of outbreaks and response activities (1-5). However, little information is available on the economic impact of measles and rubella outbreaks in a middle-income country, and in 2011, this impact was identified as a global research priority (6). Concurrent measles and rubella outbreaks in Romania provided an opportunity to estimate this economic impact.

In coordination with other World Health Organization European Region countries, Romania has a goal of measles and rubella elimination by 2020. During 2000-2003, coverage with a first dose of measles-containing vaccine in Romania was reported to be [greater than or equal to]95%; for 2004-2010, combined measles and rubella vaccine first dose coverage was [greater than or equal to]95% and second dose coverage was [greater than or equal to]88%. In spite of these high national coverage rates among recent birth cohorts, unvaccinated subpopulations exist among older age cohorts and subnationally, which create conditions for continued measles or rubella outbreaks.

During 2011-2012, Romania experienced concurrent outbreaks of measles and rubella. Measles cases were primarily reported among children from the northwest part of the country, and rubella cases were reported primarily among adolescents and adults throughout Romania. The outbreaks resulted in 12,427 measles cases and 24,627 rubella cases during 2011-2012 (the number of measles cases officially associated with the outbreak was subsequently revised to 12,234 after our analysis was conducted) (7). We estimated the economic cost of these outbreaks and response activities incurred by the health sector and households of persons with measles or rubella infection.


Definitions and Costs

We assessed the cost of the measles and rubella outbreaks by collecting data on direct and indirect costs from households and the health sector. We defined economic cost as the sum of financial costs (i.e., the monetary value of goods and services provided to treat case-patients and to contain the outbreak) and opportunity costs (i.e., the value of the best alternative forgone by the health sector or households caused by measles or rubella illness or treatment) by using the societal costing perspective. The health sector included government entities from primary to tertiary level (i.e., health facilities, agencies, or departments) involved in providing treatment to measles or rubella case-patients and in designing and implementing the public health response to the outbreaks.

Data Sources and Collection Process

Household Direct and Indirect Costs

To collect household costs, we conducted a survey among a purposely selected sample of households that had recent cases (within the previous 18 months to minimize recall bias) drawn from the national measles and rubella surveillance database (Table 1; Appendix Figure, article/25/6/18-03 39-App 1.pdf). An initial sample of 1,217 persons met the inclusion criteria; of these, 789 case-patients or their representatives could not be reached or declined to participate and 428 were interviewed (response rate 35%).

Healthcare Provider Costs

Reimbursement data were obtained from the National Health Insurance House (Casa Nationala de Asigurari de Sanatate), which covered all registered government healthcare providers in Romania (Table 1). There were [approximately equal to]10,000 primary care physicians or family doctors and >500 secondary or tertiary hospitals in the 42 health districts in Romania (8). Reimbursement fees are typically paid when doctors and hospitals submit claims to national health insurance funds for the service provided.

National Outbreak Response Costs

To assess national outbreak response costs, personnel involved in outbreak response activities were interviewed on the basis of referral from the National Institute for Public Health, Romanian Ministry of Health, which was charged with coordinating the national outbreak response. These open-ended interviews were conducted by members of the research team in Romanian at the offices of respondents and focused on collecting information about actual expenses incurred in measles and rubella outbreak response activities, including costs of enhanced surveillance, outbreak investigation, and outbreak response vaccination and vaccine stockpiling (Table 1).

Congenital Rubella Syndrome Costs

We requested reimbursement data for health services received by the 27 identified congenital rubella syndrome (CRS) cases from birth up to the date of data collection (at which point the surviving 15 CRS case-patients were 3-4 years old) from the National Health Insurance House; we obtained records for 18 (11 surviving and 7 who had died) of the 27 case-patients. The projection of their lifetime productivity losses used the same data sources and definitions as the main analysis of costs during the outbreak (Table 1). These 27 CRS case-patients were the only CRS cases included in the calculation of CRS costs during the outbreak.

All data collection activities occurred from mid-January through the end of May 2014. A post-hoc analysis of the costs of CRS cases was conducted in March-May 2016.

Data Analysis

We analyzed data by using Access and Excel (Microsoft,, and Stata version 13 (StataCorp LLC, We calculated districtlevel weights on the basis of the number of measles and rubella cases as a proportion of the total population in each of the 42 districts of Romania. We then applied these weights to the household survey data, with the costs reported by a respondent multiplied by the weight of the district in which that respondent resided, to estimate the mean, median, and interquartile range of treatment expenditures per household for measles and rubella infections and the proportion of cases receiving treatment by admission status.

We calculated the indirect costs of measles or rubella infections by first calculating the number of measles and rubella case-patients and caregivers [greater than or equal to] 18 years of age who were employed (based on employment rates reported in the patient survey). We then assumed that each of these employed case-patients and caregivers [greater than or equal to] 18 years of age lost the average number of workdays missed on the basis of the household survey. We valued each day of work missed at the minimum wage of Romania.

We used a human capital approach to estimate the lifetime productivity losses for CRS case-patients (9). We assumed that had these children not been born with CRS, their working years would have been 18-63 years of age (until median retirement age in Romania) with the same labor force participation, employment rates, minimum wage, and exchange rate during these years as those used in the main analysis (i.e., constant 2012-2013 rates). We discounted lifetime productivity losses to 2013 US dollars by using a 3% discount rate.

All costs were adjusted for inflation by using the Romanian Consumer Price Index to 2013 prices and converted from Romanian local currency (Lei) into US dollars by using 2013 exchange rates (3.32 Lei/1 US dollar). Costs are presented in 2013 US dollars (10,11).

Sensitivity Analysis

We conducted univariate sensitivity analysis to characterize how total costs would change with different input values to reflect uncertainty. Reported number of outbreak cases, healthcare provider costs, and national outbreak response costs varied by [+ or -] 10%. Out-of-pocket treatment costs, number of days of work missed by cases and caregivers, and CRS case direct medical costs varied from the 25th to 75th percentiles, and proportion of cases receiving care varied from the 5th to 95th percentiles of the sample distribution. CRS case indirect costs were also calculated from birth to an average life expectancy of 74 years.

Ethics Approval and Informed Consent

The assessment protocol was approved by the Romanian National Health Research Ethics Review Board and determined not to be human subjects research by the US Centers for Disease Control and Prevention. Informed consent was obtained from participants after the objectives of the assessment were described to them. Participants were informed that the information would be confidential, there were no unique identifiers, and that participation was voluntary. The authors certify that this study has been conducted in an ethical way according to the international standards for authors.


A retrospective review of the Romanian national measles and rubella surveillance database showed that 12,427 laboratory-confirmed and epidemiologically linked cases of measles and 24,627 laboratory-confirmed and epidemiologically linked cases of rubella were reported during the 2011-2012 outbreaks (Figure). In addition, 27 confirmed cases of CRS were reported.

Household Survey Results

The number of households with measles or rubella cases that were included in the survey was evenly split between urban and rural areas, and 46% of case-patients were employed (Table 2). Although approximately one third of responding measles or rubella case-patients were <18 years of age, more case-patients in this age range were infants and preschoolers for measles (85%) than for rubella (44%). A slightly higher proportion of rubella case-patients (10%) sought care on multiple occasions compared with measles case-patients (4%). However, measles case-patients were 3.5 times more likely to have been admitted to a hospital than rubella case-patients (Table 2). Few measles or rubella case-patients (<2%) sought care at a private health facility. The distribution of sampled case-patients by sex was similar to those for the outbreaks overall, whereas in terms of age the sampled case-patients included a higher share of adults >18 years of age than the outbreaks overall.

Household Direct Medical and Nonmedical Costs

More than 90% of responding households with either measles or rubella cases incurred some type of treatment expense (Table 2). Case-patients with measles (36%) and rubella (7%) reported having to borrow money to pay for costs related to an episode of measles or rubella (Table 2). The largest share of household spending was on medications, followed by transportation. We found no notable differences in transportation or overall spending for households residing in rural areas compared with those in urban settings, which might reflect the history of widespread geographic availability of healthcare by state-owned polyclinics throughout Romania. Average household spending for measles and rubella patients <18 years old was more than that for patients [greater than or equal to] 18 years old (US $112.51 vs. US $45.85). Weighted median inpatient costs for measles were 2.2 times higher than for rubella, and outpatient costs for measles were 1.5 times higher than for rubella (Table 3). Total estimated direct medical and nonmedical household costs for treatment were US $888,338 for the 12,427 measles cases and US $477,261 for the 24,627 rubella cases (Table 4).

Household Indirect Costs

Among responding patients participating in the labor market, a median of 11.45 days were lost for measles and 9.62 days for rubella (Table 3). The maximum number of workdays lost were 68 days for a single episode of measles and 21 days for an episode of rubella. Of those [greater than or equal to] 18 years of age, 27% reported working while ill. Among those who continued to work, the average number of days worked while ill with measles or rubella was 4 days. Students and schoolchildren reported an average of 10 days that they were unable to attend school because of measles or rubella infection. Total estimated indirect household costs were US $779,917 for the 12,427 measles cases and US $1,043,281 for the 24,627 rubella cases (Table 4).

Total Estimated Household Costs

We determined total estimated direct and indirect household costs. These values were US $1.7 million for 12,427 measles cases (US $133.84/case) and US $1.5 million for 24,627 rubella cases (US $61.74/case) (Tables 4, 5).

Healthcare Provider Costs

Healthcare providers received direct reimbursement fees from health insurance. These totals were US $3,275,757 for services provided to treat measles and US $674,633 for services provided to treat rubella infections during the outbreak (Table 4).

National Outbreak Response Costs

National response activities included enhanced surveillance, laboratory diagnostic testing, and immunization of at-risk populations at a total cost of US $1,559,975, of which [approximately equal to]60% were for activities related to diagnosis and containment of rubella (Table 4). Virtually equal amounts of national resources were spent on measles and rubella containment efforts per case (US $41.55/case for measles and US $42.38/case for rubella) (Table 5). Most (87%) costs were incurred for laboratory reagents, laboratory tests, and overtime salaries for laboratory technicians (Table 3).

CRS Case Costs

Estimated health service reimbursement costs for the 27 CRS cases up to May 2016 were US $130,143 (Table 4). Estimated discounted lifetime productivity losses for the 12 CRS case-patients who had died by May 2016 were US $470,774. Under the assumption that the 15 surviving CRS case-patients would also be unable to work during their lifetimes, their estimated discounted lifetime productivity losses would be US $588,467 (US $1,059,241 for all 27 case-patients) (Table 4).

Societal Costs

Total societal costs of the measles and rubella outbreaks were US $9.9 million, of which US $5.5 million was for measles-related activities and US $4.4 million for rubella-related activities (the rubella-related activities included US $1.2 million in CRS-related costs) (Table 4). These costs translated to a total cost per case of US $439 for measles, US $132 for rubella (not including CRS), and US $44,051 for CRS (Table 5). Sensitivity analysis showed that total costs varied between US $9,266,779 (when the lower bound of measles treatment costs was used) and US $10,989,560 (when the upper bound of lifetime CRS case indirect costs was used) (Table 4).


The large concurrent outbreaks of measles and rubella in Romania provided a major opportunity for an economic assessment of both diseases, as well as for CRS, in a middle-income country setting. Our key study findings were that households incurred a high economic burden of measles or rubella infection compared with income, the health sector bore most of the economic cost of the measles and rubella outbreaks, and CRS case costs were substantial and relevant to include in rubella outbreak cost studies. Our study contributes to the limited literature on measles and rubella outbreak costs in middle-income countries and to the evidence gap in this global research priority.

The economic burden of the measles and rubella outbreaks on the outbreak-affected households was substantial. Almost every household incurred costs relating to measles or rubella treatment. The direct household cost per case of measles or rubella was high compared with the average income in Romania in 2012: 30% of monthly income and 3% of annual income for measles, 9% of monthly income and 1% of annual income for rubella. Previous studies indicated that, when illness-related economic costs are >10% of annual household income, it is considered catastrophic because it potentially forces households to cut consumption of necessities, such as food and water, and leads to increased debt or greater poverty (12-14). Although direct household costs per case in our study in general did not exceed this threshold in Romania ([approximately equal to]US $263 in 2013), the highest cost households did; moreover, these costs were for only 1 medical event, and the financial burden would increase if other illnesses were considered.

For households, the unexpected measles and rubella treatment costs had to be met in the short term. High medical costs incurred in a short period are considered more detrimental than high costs incurred over a long period (12). Approximately 36% of households with measles and 7% with rubella reported borrowing money to pay for these expenses. Similar medical bill coping strategies, including informal payments, have also been confirmed in other studies in Romania (15,16). As a consequence of these expenses, studies in Romania and other countries in eastern Europe have reported that up to 60% of patients are forced to postpone or completely forgo treatments because of lack of money to pay their medical bills (15,17). Because per capita health spending in Romania was less than that in the United States (US $580) during 2013 (18), the estimated direct household and health sector costs per case of measles (US $376) and rubella (US $89, not including CRS costs) were high.

The health sector bore 70% of the economic cost of the outbreak for measles and 39% for the outbreak of rubella. For measles, 86% of the health sector costs were for provider reimbursement. For rubella, 61% was for national outbreak response activities. More than 85% of the national outbreak response activities were for laboratory reagents and test kits for measles and rubella, but only 12% was for emergency vaccine purchase because large-scale supplemental immunization activities were not conducted. Assuming a cost per dose administered of US $5, the cost of vaccinating all 36,861 confirmed case-patients with measles or rubella with 2 doses of the measles and rubella vaccine before the outbreak would have cost the health sector 10% of the amount paid for health sector costs for the measles outbreak and 21% of the amount paid for health sector costs for the rubella outbreak. Any pre-outbreak vaccination campaign would have had to vaccinate more than just the 36,861 persons who were infected during the outbreak to prevent the outbreak, and the costs of strategies to reach persistently unvaccinated subpopulations in Romania might be higher than typical campaign or routine immunization costs. Even so, such preemptive campaigns to reduce immunity gaps, coupled with continued robust routine immunization delivery, would have provided protection and reduced costs to the health sector, not only during the 2011-2012 outbreaks but also for future outbreaks. This finding is critical because Romania continues to have measles outbreaks.

Our study contributes to the ongoing efforts to document evidence of the economic burden of vaccine-preventable diseases in middle-income countries, with particular focus on measles and rubella. A study from Ethiopia reported an estimated household cost of US $29.18/case of measles treated during a measles outbreak in 2011 (2). As in Romania, the Ethiopian health sector bore most (80%) of the outbreak cost. A study in Latin America found the costs of measles treatment to range from US $43 in Nicaragua to US $210 in Argentina; the average cost was US $190 for the entire Latin America region (19). As an upper-middle-income country, economic costs for Romania are more comparable to those reported for countries such as the Netherlands, the United Kingdom, and Canada; a study from these countries in 2002 reported the societal costs of measles treatment as US $254 in Canada, US $276 in the Netherlands, and US $307 in the United Kingdom (20).

Our post-hoc analysis of CRS direct medical costs and estimated productivity losses adds to the limited literature on CRS costs in different economic settings (21). Studies from Brazil, Oman, and Uzbekistan reported that estimated CRS costs ranged from US $18,644 to >US $1.18 million/ case (22-24). More than 90% of these costs constitute indirect CRS costs. Future studies of CRS economic burden in low- and middle-income countries are needed. In this assessment, we did not quantify the value of life lost because of measles or rubella infections occurring during the outbreak, aside from the CRS cost estimates.

Our cost estimates are subject to several limitations. The household cost estimates were retrospective, and some persons might have been susceptible to recall bias. The purposive sampling of recent cases and district-level weighting procedures used for the household survey do not necessarily provide a nationally representative estimate of household costs, and no adjustment was made to account for survey nonresponse (response rate 35%), which might introduce selection bias; household costs might be underestimated because of the smaller proportion of case-patients <18 years of age in our sample compared with the outbreaks overall. We only recorded the provider reimbursement claims that were actually paid by the national insurance companies. However, anecdotal information suggested that claims were sometimes reimbursed at lower standard amounts based on limited availability of funds at the national level. National outbreak response costs were based on interviews with key informants from the agencies responsible for response implementation and are believed to be exhaustive of the costs incurred. However, other agencies might have also provided outbreak response and might not have been known to the national health authorities we used as key informants for the agencies involved in outbreak response.

For the CRS cost analysis, we did not obtain information on 9 of the reported cases (response rate 67%), which might introduce selection bias in our results, although no systematic differences in clinical profiles between included and excluded cases were observed. Information on some types of future CRS care costs (e.g., special schooling, government disability payments) were not available and are therefore not included in the analysis. The CRS productivity losses assume that all surviving case-patients are fully unable to work; this assumption might overestimate the indirect costs of CRS if some of these case-patients are ultimately able to work for income. Because of the nonrepresentative sampling techniques used and nonresponse, no uncertainty bounds were calculated for these cost estimates. Finally, the estimation of economic costs was not fully comprehensive. The opportunity costs of healthcare workers devoting their time to doing other public health activities was not estimated because of incomplete data.

In conclusion, the costs of the 2011-2012 measles and rubella outbreaks in Romania were high, especially when compared with total average household incomes and national health expenditures per capita. In addition to the health consequences of these outbreaks, households faced major threats of financial insecurities during these outbreaks and the long-term economic impacts of productivity losses. Preventing outbreaks through routine vaccination also reduces the economic burden on the health sector. This study makes a major contribution to identifying the overall societal economic burden of measles and rubella outbreaks in Romania and improves our understanding of the magnitude of the costs of measles and rubella outbreaks in middle-income economies.

At the time of study, Dr. Njau was an economist with the Global Immunization Program, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA. He is currently a consultant at JoDon Consulting Group LLC, Atlanta, GA. His research interests are the economics of infectious diseases, including malaria, Ebola, and vaccine-preventable diseases, such as measles, rubella, rotavirus infection, and hepatitis B.


(1.) Ortega-Sanchez IR, Vijayaraghavan M, Barskey AE, Wallace GS. The economic burden of sixteen measles outbreaks on United States public health departments in 2011. Vaccine. 2014;32:1311-7.

(2.) Wallace AS, Masresha BG, Grant G, Goodson JL, Birhane H, Abraham M, et al. Evaluation of economic costs of a measles outbreak and outbreak response activities in Keffa Zone, Ethiopia. Vaccine. 2014;32:4505-14. j.vaccine.2014.06.035

(3.) Lanzieri TM, Segatto TC, Siqueira MM, de Oliviera Santos EC, Jin L, Prevots DR. Burden of congenital rubella syndrome after a community-wide rubella outbreak, Rio Branco, Acre, Brazil, 2000 to 2001. Pediatr Infect Dis J. 2003;22:323-9. 10.1097/01.inf.0000059401.07698.95

(4.) Njeru I, Onyango D, Ajack Y, Kiptoo E. Rubella outbreak in a Rural Kenyan District, 2014: documenting the need for routine rubella immunization in Kenya. BMC Infect Dis. 2015;15:245.

(5.) Hahne S, Macey J, van Binnendijk R, Kohl R, Dolman S, van der Veen Y, et al. Rubella outbreak in the Netherlands, 2004-2005: high burden of congenital infection and spread to Canada. Pediatr Infect Dis J. 2009;28:795-800. 10.1097/INF.0b013e3181a3e2d5

(6.) Curtale F, Perrelli F, Mantovani J, Ciofi degli Atti M, Filia A, Nicoletti L, et al. Description of two measles outbreaks in the Lazio Region, Italy (2006-2007). Importance of pockets of low vaccine coverage in sustaining the infection. BMC Infect Dis. 2010;10:62.

(7.) National Public Health Institute. National Center for Surveillance and Control of Communicable Diseases. The 2011/2012 measles outbreak in Romania. Bucharest (Romania): the Institute; 2013.

(8.) Vladescu C, Scintee G, Olsavszky V. Romania health system review. In: Mladovsky SA, editor. Health systems in transition. London: The European Observatory on Health Systems and Policies; 2008 [cited 2019 Mar 17]. data/assets/pdf_file/0017/317240/Hit-Romania.pdf?ua=1

(9.) Johannesson M. The willingness to pay for health changes, the human-capital approach and the external costs. Health Policy. 1996;36:231-44. (96)00815-9

(10.) National Bank of Romania (NBR). Exchange rates: monthly, quarterly and annual averages. Bucharest (Romania): NBR; 2013.

(11.) Institut National de Statistica. Consumer price index. December 2013 edition. Bucharest (Romania); The Institut; 2016.

(12.) Xu K, Evans DB, Kawabata K, Zeramdini R, Klavus J, Murray CJ. Household catastrophic health expenditure: a multicountry analysis. Lancet. 2003;362:111-7. S0140-6736(03)13861-5

(13.) Xu K, Evans DB, Carrin G, Aguilar-Rivera AM, Musgrove P, Evans T. Protecting households from catastrophic health spending. Health Aff (Millwood). 2007;26:972-83. hlthaff.26.4.972

(14.) Raban MZ, Dandona R, Dandona L. Variations in catastrophic health expenditure estimates from household surveys in India. Bull World Health Organ. 2013;91:726-35. BLT.12.113100

(15.) Tambor M, Pavlova M, Rechel B, Golinowska S, Sowada C, Groot W. The inability to pay for health services in central and eastern Europe: evidence from six countries. Eur J Public Health. 2014;24:378-85.

(16.) Stepurko T, Pavlova M, Gryga I, Groot W. To pay or not to pay? A multicountry study on informal payments for health-care services and consumers' perceptions. Health Expect. 2014.

(17.) Atanasova E, Pavlova M, Moutafova E, Rechel B, Groot W. Out-of-pocket payments for health care services in Bulgaria: financial burden and barrier to access. Eur J Public Health. 2013;23:916-22.

(18.) The World Bank. Health expenditure per capita (current US$). World development indicators. Washington: World Bank and World Health Organization; 2013.

(19.) Acharya A, Diaz-Ortega JL, Tambini G, de Quadros C, Arita I. Cost-effectiveness of measles elimination in Latin America and the Caribbean: a prospective analysis. Vaccine. 2002;20:3332-41.

(20.) Carabin H, Edmunds WJ, Kou U, van den Hof S, Nguyen VH. The average cost of measles cases and adverse events following vaccination in industrialised countries. BMC Public Health. 2002;2:22.

(21.) Hinman AR, Irons B, Lewis M, Kandola K. Economic analyses of rubella and rubella vaccines: a global review. Bull World Health Organ. 2002;80:264-70.

(22.) Lanzieri TM, Parise MS, Siqueira MM, Fortaleza BM, Segatto TC, Prevots DR. Incidence, clinical features and estimated costs of congenital rubella syndrome after a large rubella outbreak in Recife, Brazil, 1999-2000. Pediatr Infect Dis J. 2004;23:1116-22.

(23.) Al-Awaidy S, Griffiths UK, Nwar HM, Bawikar S, Al-Aisiri MS, Khandekar R, et al. Costs of congenital rubella syndrome (CRS) in Oman: evidence based on long-term follow-up of 43 children. Vaccine. 2006;24:6437-45. j.vaccine.2006.05.089

(24.) Kurbanov B, Musabaev E, Latipov R. The economic burden of congenital rubella syndrome and vaccination in Tashkent City, Uzbekistan. EpiNorth. 2012;13:18-24.

Address for correspondence: Laura Zimmerman, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop H24-3, Atlanta, GA 30329-4017, USA; email:

Joseph Njau, [1] Denisa Janta, Aurora Stanescu, Sarah L. Pallas, Adriana Pistol, Nino Khetsuriani, [2] Susan Reef, Daniel Ciurea, Cassandra Butu, Aaron S. Wallace, Laura Zimmerman

Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (J. Njau, S.L. Pallas, S. Reef, A.S. Wallace, L. Zimmerman); National Public Health Institute, Bucharest, Romania (D. Janta, A. Stanescu, A. Pistol); Centers for Disease Control and Prevention, Tbilisi, Georgia (N. Khetsuriani); Center for Health Policies and Services, Bucharest (D. Ciurea); World Health Organization Country Office, Bucharest (C. Butu)


[1] Current affiliation: JoDon Consulting Group LLC, Atlanta, Georgia, USA.

[2] Current affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Caption: Figure. Reported cases of measles and rubella during concurrent outbreaks, Romania, 2011-2012. Values reflect revision of official case counts after analysis was completed.
Table 1. Definitions and data sources used for cost components
during assessment of economic burden of concurrent measles and
rubella outbreaks, Romania, 2011-2012 *

Cost component               Definition              Data sources

Healthcare provider    All reimbursements for     Reimbursement data
                       diagnostic testing for    from National Health
                        measles and rubella,    Insurance House (CNAS)
                           inpatient and             covering all
                          outpatient care,      registered government
                        emergency treatment,     healthcare providers
                          case management         using the Romanian
                                                  national clinical
                                                   diagnosis codes
                                                   associated with
                                                 measles and rubella
                                                diagnoses, outpatient
                                                 and inpatient care,
                                                   and vaccinations
                                                   (Appendix Table,

National outbreak      Enhanced surveillance,    Interviews with key
response                laboratory diagnosis     personnel, including
                         and confirmation,       the Director of the
                       field activities such    National Institute for
                              as case               Public Health,
                        investigations, and     Romanian MOH; the Team
                         outbreak response      Leads for Measles and
                           immunization,          Rubella, National
                          including actual            Center for
                       expenses incurred for       Surveillance and
                       personnel, laboratory          Control of
                       supplies, and vaccine    Communicable Diseases,
                         doses provided to        MOH; a measles and
                       contacts of cases and    rubella epidemiologist
                            to high-risk          from the District
                            communities             Public Health
                                                Authorities, MOH; the
                                                   Director of the
                                                  department and an
                                                    analyst at the
                                                   National Health
                                                   Insurance House
                                                 (CNAS); and the Head
                                                of Country Office and
                                                   a public health
                                                 officer at the World
                                                 Health Organization
                                                  country office in

Direct medical and      Medical costs (e.g.,     Household survey of
nonmedical household     consultation fees,        428 recent case-
                        laboratory tests and    patients (within last
                          medications) and       18 months) by using
                          nonmedical costs       structured telephone
                       (e.g., transport, food         interviews
                       and lodging) paid out-
                       of-pocket by cases and

Indirect household     Workdays lost by cases    Household survey of
                       and caregivers because      428 recent case/
                       of measles or rubella    patients (within last
                             infections          18 months) by using
                                                 structured telephone
                                                   interviews; 2012
                                                  Romanian national
                                                 minimum wage of 700
                                                Lei/month was used as
                                                proxy to quantify the
                                                value of lost workdays
                                                   by patients and
                                                 caretakers [greater
                                                than or equal to] 18 y
                                                     of age (8).

CRS cases healthcare       All diagnostic         Reimbursement data
provider                services, inpatient      from National Health
                        and outpatient care     Insurance House (CNAS)
                       reimbursements related        covering all
                         to CRS diagnostic      registered government
                        codes for identified     healthcare providers
                          CRS cases during       for the 27 CRS cases
                             timeframe           identified from the
                                                 time of the outbreak
                                                up to the date of data
                                                  reimbursement data
                                                 were obtained for 18
                                                 (11 surviving and 7
                                                 who had died) of the
                                                   27 case-patients

CRS cases lifetime      Workdays lost by CRS    2012 Romanian national
discounted indirect      cases over assumed      minimum wage of 700
                        lifetime productive     Lei/month was used as
                        working years (18-63     a proxy to quantify
                                 y)               the value of lost
                                                 workdays by patients
                                                [greater than or equal
                                                  to]18 y of age (8)

* CNAS, Casa Nationala de Asigurari de Sanatate; CRS, congenital
rubella syndrome; MOH, Ministry of Health.

Table 2. Descriptive characteristics of case-patients responding to
household survey for assessment of economic burden of concurrent
measles and rubella outbreaks, Romania, 2011-2012

                                            No. (%) case-patients

Characteristic                         Measles    Rubella     Total

Total sample                             219        209        428
  Age <18 y                            74 (34)    63 (30)    137 (32)
  Male sex                             109 (50)   107 (51)   216 (50)
  Urban domicile                       98 (55)    115 (45)   213 (50)
  Multiple care visits                  8 (4)     21 (10)     29 (7)
  Admission to hospital                185 (84)    38 18)    223 (52)
  Care at private clinics               3 (1)      4 (2)      7 (2)
Age [greater than or equal to]18 y       145        146        291
  Formal or informal employment        72 (50)    63 (43)    135 (46)
  Students                              13 (9)    66 (45)    79 (27)
  Retired, unemployed, or housewives   60 (41)    17 (12)    77 (26)

Age <18 y                                 74         63        137
  Infants and preschoolers             63 (85)    28 (44)    91 (66)
  Schoolchildren                       11 (15)    35 (56)    46 (34)

Treatment expenses                       219        209        428
  Incurred some treatment expenses     206 (94)   194 (93)   400 (93)
  Borrowed money for treatment
    expenses                           79 (36)     14 (7)    93 (22)

Table 3. Main analysis input and sensitivity analysis values used
for cost analysis of economic burden of concurrent measles and
rubella outbreaks, Romania, 2011-2012 *

component      Disease                   Input

Case           Measles                 No. cases
distribution   Rubella                 No. cases
               Rubella               No. CRS cases
               Rubella     Patients who died as of May 2016
               Rubella      Patients who survived as of May
               Measles             Cases in 2011, %
               Measles             Cases in 2012, %
               Rubella             Cases in 2011, %
               Rubella             Cases in 2012, %

Healthcare     Measles        Reimbursement to healthcare
provider                 providers for diagnostic codes, 2011
               Measles        Reimbursement to healthcare
                         providers for diagnostic codes, 2012
               Rubella        Reimbursement to healthcare
                         providers for diagnostic codes, 2011
               Rubella        Reimbursement to healthcare
                         providers for diagnostic codes, 2012
National       Measles            Personnel time for
outbreak                           outbreak response
response       Measles    Reagent/test for outbreak response
               Measles        Emergency vaccine purchases
               Rubella            Personnel time for
                                   outbreak response
               Rubella    Reagent/test for outbreak response
               Rubella        Emergency vaccine purchases

Direct         Measles   Out-of-pocket cost for inpatient care
and            Rubella   Out-of-pocket cost for inpatient care
household      Measles          Out-of-pocket cost for
                                    outpatient care
               Rubella          Out-of-pocket cost for
                                    outpatient care
               Measles   Patients receiving outpatient care, %
               Measles   Patients receiving inpatient care, %

               Rubella   Patients receiving outpatient care, %
               Rubella   Patients receiving inpatient care, %

Indirect       Measles     Employment rate for case-patients
household                          and caregivers, %
               Rubella     Employment rate for case-patients
                                   and caregivers, %
               Measles           No. work days missed
                                   by case-patients
               Rubella           No. work days missed
                                   by case-patients
               Measles    Case caregivers who missed work, %
               Rubella    Case caregivers who missed work, %
               Measles    No. work days missed by caregivers
               Rubella    No. work days missed by caregivers
               Both               Minimum daily wage

CRS, direct    Rubella        Reimbursement to healthcare
medical                   providers for patients who survived
               Rubella        Reimbursement to healthcare
                            providers for patients who died

CRS,           Rubella            Minimum daily wage
lifetime       Rubella    Years (range) of productivity loss
discounted     Rubella     Labor force participation rate, %
indirect       Rubella           Unemployment rate, %
               Rubella             Discount rate, %

Cost                                     Median (25th-     Proportion
component      Disease   Input value   75th percentiles)    (95% CI)

Case           Measles     12,427             NA               NA
distribution   Rubella     24,627             NA               NA
               Rubella       27               NA               NA
               Rubella       12               NA               NA
               Rubella       15               NA               NA

               Measles       39               NA               NA
               Measles       61               NA               NA
               Rubella       16               NA               NA
               Rubella       85               NA               NA

Healthcare     Measles   $1,313,049           NA               NA
               Measles   $1,962,708           NA               NA

               Rubella    $107,494            NA               NA

               Rubella    $567,138            NA               NA

National       Measles     $5,164             NA               NA
response       Measles    $449,225            NA               NA
               Measles     $61,962            NA               NA
               Rubella     $10,437            NA               NA

               Rubella    $907,951            NA               NA
               Rubella    $125,235            NA               NA

Direct         Measles       NA             $66.87             NA
medical                                ($21.27-$110.94)
and            Rubella       NA             $30.70             NA
nonmedical                              ($15.20-$82.06)
household      Measles       NA             $18.23             NA
               Rubella       NA             $12.50             NA
               Measles       NA               NA           19 (24-60)
               Measles       NA               NA               81
               Rubella       NA               NA           62 (17-27)
               Rubella       NA               NA           38 (24-91)

Indirect       Measles       34               NA               NA
               Rubella       32               NA               NA

               Measles       NA          11.45 (7-18)          NA

               Rubella       NA           9.62 (7-14)          NA

               Measles       89               NA               NA
               Rubella       68               NA               NA
               Measles       NA            7 (3-10)            NA
               Rubella       NA            4.5 (3-7)           NA
               Both        $10.44             NA               NA

CRS, direct    Rubella       NA             $6,455             NA
medical                                ($1,749-$10,296)
               Rubella       NA             $2,777             NA

CRS,           Rubella     $10.44             NA               NA
lifetime       Rubella   46 (18-63)           NA               NA
discounted     Rubella       65               NA               NA
indirect       Rubella       11               NA               NA
               Rubella        3               NA               NA

Cost                     Sensitivity   Sensitivity
component      Disease   analysis LB   analysis UB

Case           Measles     11,184        13,670
distribution   Rubella     22,164        27,090
               Rubella       NA            NA
               Rubella       NA            NA
               Rubella       NA            NA

               Measles       NA            NA
               Measles       NA            NA
               Rubella       NA            NA
               Rubella       NA            NA

Healthcare     Measles   $1,181,744    $1,444,353
               Measles   $1,766,437    $2,158,979

               Rubella     $96,745      $118,244

               Rubella    $510,425      $623,852

National       Measles     $4,648        $5,680
response       Measles    $404,303      $494,148
               Measles     $55,766       $68,158
               Rubella     $9,393        $11,481

               Rubella    $817,156      $998,746
               Rubella    $112,712      $137,759

Direct         Measles     $21.27        $110.94
and            Rubella     $15.20        $82.06
household      Measles      $4.55        $39.51

               Rubella      $6.07        $24.32

               Measles       24            60
               Measles       80            100

               Rubella       17            27
               Rubella       34            91

Indirect       Measles       NA            NA
               Rubella       NA            NA

               Measles        7            18

               Rubella        7            14

               Measles       NA            NA
               Rubella       NA            NA
               Measles        3            10
               Rubella        3             7
               Both          NA            NA

CRS, direct    Rubella     $1,749        $10,296
               Rubella     $1,734        $3,309

CRS,           Rubella       NA            NA
lifetime       Rubella       NA          74 (LE)
discounted     Rubella       NA            100
indirect       Rubella       NA             0
               Rubella       NA            NA

* Monetary values are in US 2013 dollars. CRS is an outcome of
rubella. CRS, congenital rubella syndrome; LB, lower bound; LE, life
expectancy; NA, not applicable; UB, upper bound.

Table 4. Estimated total costs by component for base case and
sensitivity analyses for assessment of economic burden of concurrent
measles and rubella outbreaks, Romania, 2011-2012 *

                 Disease or   Main analysis      Sensitivity
Cost component    outcome       base case     analysis variable

Healthcare        Measles      $3,275,757         Healthcare
provider                                        provider costs
                  Rubella       $674,633          Healthcare
                                                provider costs

National          Measles       $516,351      National outbreak
outbreak                                        response costs
response          Rubella      $1,043,623     National outbreak
                                                response costs

Direct medical    Measles       $883,338        Out-of-pocket
and nonmedical                                  inpatient and
household                                         outpatient
                                               treatment costs
                                                Proportion of
                                              patients receiving
                                                 inpatient or
                                                  No. cases
                  Rubella       $477,261        Out-of-pocket
                                                inpatient and
                                               treatment costs
                                                Proportion of
                                              patients receiving
                                                 inpatient or
                                                  No. cases

Indirect          Measles       $779,917        No. work days
household                                      missed by case-
                                                No. work days
                                                  missed by
                  Rubella      $1,043,281       No. work days
                                               missed by case-
                                                No. work days
                                                  missed by

CRS cases         Rubella       $130,143        Reimbursement
direct medical                                  to healthcare
                                              providers for CRS

CRS cases         Rubella      $1,059,241      Productive years
lifetime                                         (labor force
discounted                                      participation,
indirect                                         unemployment

Total             Measles      $5,455,363             NA
                  Rubella      $4,428,182             NA
                    Both       $9,883,545             NA

                 Disease or   Sensitivity   Sensitivity
Cost component    outcome     analysis LB   analysis UB

Healthcare        Measles     $2,948,181    $3,603,332
                  Rubella      $607,169      $742,096

National          Measles      $464,716      $567,986
response          Rubella      $939,261     $1,147,985

Direct medical    Measles      $266,573     $1,572,347
and nonmedical

                               $716,509      $915,498

                               $795,004      $971,672
                  Rubella      $141,497     $1,136,431

                               $310,302      $768,764

                               $429,535      $524,988

Indirect          Measles      $583,614     $1,068,856

                               $622,875      $897,698

                  Rubella      $827,714     $1,403,658

                               $959,358     $1,183,153

CRS cases         Rubella       $47,038      $194,145
direct medical

CRS cases         Rubella         NA        $2,165,257

Total             Measles         NA            NA
                  Rubella         NA            NA
                    Both          NA            NA

                              Total measles   Total measles
                 Disease or    and rubella     and rubella
Cost component    outcome     costs with LB   costs with UB

Healthcare        Measles      $9,555,968      $10,211,120
                  Rubella      $9,816,081      $9,951,007

National          Measles      $9,831,909      $9,935,179
response          Rubella      $9,779,182      $9,987,906

Direct medical    Measles      $9,266,779      $10,572,553
and nonmedical

                               $9,716,715      $9,915,704

                               $9,795,210      $9,971,878
                  Rubella      $9,547,779      $10,542,713

                               $9,716,584      $10,175,046

                               $9,835,818      $9,931,270

Indirect          Measles      $9,687,241      $10,172,484

                               $9,726,502      $10,001,325

                  Rubella      $9,667,976      $10,243,920

                               $9,799,621      $10,023,416

CRS cases         Rubella      $9,800,438      $9,947,546
direct medical

CRS cases         Rubella          NA          $10,989,560

Total             Measles          NA              NA
                  Rubella          NA              NA
                    Both           NA              NA

* CRS, congenital rubella syndrome; LB, lower bound;
NA, not applicable; UB, upper bound.

Table 5. Estimated overall cost per case of measles, rubella, or
congenital rubella syndrome during concurrent outbreaks, Romania,
2011-2012 *

                                    Cost per case (sensitivity
                                     analysis lower bound-upper
                                         bound; 2013 US $)

Cost type                           Measles       Rubella, not CRS

Household direct medical
  and nonmedical                $71 ($21-$127)      $19 ($6-$46)
Household indirect               $63 ($47-$86)     $42 ($34-$57)
Healthcare provider             $264 ($237-290)     $27 ($25-30)
National outbreak response       $42 ($37-46)       $42 ($38-47)
CRS cases direct medical              NA                 NA
CRS cases lifetime discounted
  indirect                            NA                 NA
Estimated total societal/case   $439 ($389-494)   $132 ($118-$158)

                                Cost per case (sensitivity
                                analysis lower bound-upper
                                     bound; 2013 US $)

Cost type                                   CRS

Household direct medical
  and nonmedical                            NA
Household indirect                          NA
Healthcare provider                         NA
National outbreak response                  NA
CRS cases direct medical          $4,820 ($1,742-$7,191)
CRS cases lifetime discounted
  indirect                         $39,231 (UB: $80,195)
Estimated total societal/case    $44,051 ($40,973-$85,015)

* CRS, congenital rubella syndrome; NA, not applicable; UB, upper
bound of sensitivity analysis.
COPYRIGHT 2019 U.S. National Center for Infectious Diseases
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:RESEARCH
Author:Njau, Joseph; Janta, Denisa; Stanescu, Aurora; Pallas, Sarah L.; Pistol, Adriana; Khetsuriani, Nino;
Publication:Emerging Infectious Diseases
Article Type:Clinical report
Geographic Code:4EXRO
Date:Jun 1, 2019
Previous Article:Patterns of Abundance, Host Use, and Everglades Virus Infection in Culex (Melanoconion) cedecei Mosquitoes, Florida, USA.
Next Article:Novel Orthobunyavirus Causing Severe Kidney Disease in Broiler Chickens, Malaysia, 2014-2017.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters